IceCure Medical yesterday released data from an interventional radiology study of its liquid-nitrogen-based cryoablation technology.
Results from the study were presented at the Annual European Association of Urology Congress in Barcelona, the Israel-based company said.
IceCure Medical’s ProSense cryoablation system uses liquid nitrogen technology for the treatment of benign and cancerous tumors through freezing, the company said.
“The ProSense system has already demonstrated excellent progress as a rapid, in-office solution for the treatment of breast tumors. This new data adds to our growing clinical evidence for its expanding use in the field of interventional oncology as a non-surgical alternative to treat cancer of the kidney, lung, bone, and prostate,” CEO Eyal Shamir said in a prepared statement.
Researchers explored the use of the ProSense system in treating 75 patients with 78 reported small kidney masses, IceCure said.
Data from the study indicated that the system was safe and effective at treating the small kidney tumors, with a 93% treatment success rate identified by lack of enhancement on computed tomography or magnetic resonance imaging at 1-year post treatment.
“The ProSense system enables a safe, efficient and short minimal-invasive procedure that preserves renal function. There were over 400,000 new cases world-wide in 2018. The ProSense system adds a viable option to treat renal cancer in patients who have at least one comorbidity, had surgeries in the past or are a subject to multiple renal masses,” principal study investigator Dr. Ofer Nativ of Bnei Zion Hospital Urology Department said in a press release.
